Since April 2017, midostaurin has been approved by the Food and Drug Administration (FDA) for the treatment of patients with newly diagnosed FLT3-mutated AML or patients with systemic mastocytosis with associated blood neoplasm or mast cell leukemia. Here, FLT3 is linked to acute myeloid leukemia.